- 01$3m grant backs EMVision’s portable TBI scanner.
- 02Trials target brain bleeds, with work starting in 2027.
- 03Trauma use could more than double potential scans.
EMVision Medical Devices (ASX: EMV) has been awarded a $3 million federal grant to develop and clinically test its portable First Responder brain scanner for suspected traumatic brain injury (TBI).
The funding will support a second proposed clinical application for the device, building on its existing development work to detect bleeding associated with stroke.
The grant was awarded under round 19 of the Australian government’s Cooperative Research Centres Projects (CRC-P) program.
EMVision expects project work to begin in the first quarter of 2027, with clinical study activation planned for the second half of that year.
Second Clinical Application
The project will investigate whether First Responder can identify bleeding inside the skull following a head injury, using diagnostic technology being developed for stroke assessment.
The battery-powered, non-ionising scanner is designed to be carried to patients, potentially allowing paramedics and clinicians to assess suspected brain bleeding before hospital arrival.
Patients with suspected TBI currently commonly require hospital computed tomography (CT) imaging to establish whether a bleed is present, particularly when symptoms are subtle.
Testing will compare scans from patients with suspected injuries against hospital CT or magnetic resonance imaging, with researchers measuring preliminary detection accuracy and assessing device safety.
EMVision will explore possible concussion assessment applications, although the immediate focus remains detection of traumatic bleeding.
Wider Portable Scanning Market
Falls are a leading cause of TBI, particularly among older people, making aged care a potential additional setting for the technology alongside emergency services and military operations.
EMVision estimates that more than 50 million people sustain TBI worldwide each year, with about 200,000 events annually in Australia.
In the US, an estimated 2.8 million TBI-related emergency department visits, hospitalisations, and deaths occur annually, compared with approximately 800,000 strokes.
The company estimates adding trauma assessment could more than double the potential number of scans per First Responder under its planned per-scan consumables model, although this is not a revenue forecast.
Third CRC-P Grant Award
The new award marks EMVision’s third under the program, and is separate from the $3m CRC-P grant the company received in 2025 for the emu Regional Benefits Study.
CRC-P requires matched cash or in-kind contributions, while the latest funding remains conditional on agreements with the Commonwealth and project partners.
Metro North Hospital and Health Service and Titan Prehospital Innovation are participating, with EMVision targeting completion of the agreements in the coming months.
The company plans to establish clinical protocols and obtain ethics approvals in the first half of 2027 before commencing patient recruitment and preliminary validation work.
Strong TBI Foundation
“A single portable device that can detect a bleed in minutes at the point of care—for both stroke and trauma—and bring treatment and transfer decisions forward to the moment of first contact is a particularly compelling proposition for patients and healthcare systems,” managing director Scott Kirkland said.
“Fresh blood has the same dielectric properties whether it comes from a stroke or a head injury, and as a result, the bleed detection capability we are building into our First Responder for stroke, alongside acute ischaemia detection, gives us a strong foundation for TBI.”
The company intends to use the clinical findings to determine the sensitivity and specificity of its trauma detection algorithms and guide subsequent regulatory studies.
First Responder remains an investigational device and is not approved for detecting TBI or bleeding inside the skull in any jurisdiction, with any future trauma indication dependent upon satisfactory clinical evidence and regulatory clearance.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.
